These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17216011)

  • 21. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
    Johnson V; Lipton LR; Cummings C; Eftekhar Sadat AT; Izatt L; Hodgson SV; Talbot IC; Thomas HJ; Silver AJ; Tomlinson IP
    J Med Genet; 2005 Oct; 42(10):756-62. PubMed ID: 15788729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Colon carcinoma: molecular diagnosis and therapy].
    Blum HE
    Praxis (Bern 1994); 1997 Sep; 86(39):1504-9. PubMed ID: 9411670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J
    Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MSI-low, a real phenomenon which varies in frequency among cancer types.
    Halford SE; Sawyer EJ; Lambros MB; Gorman P; Macdonald ND; Talbot IC; Foulkes WD; Gillett CE; Barnes DM; Akslen LA; Lee K; Jacobs IJ; Hanby AM; Ganesan TS; Salvesen HB; Bodmer WF; Tomlinson IP; Roylance RR
    J Pathol; 2003 Nov; 201(3):389-94. PubMed ID: 14595750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hereditary colorectal cancer syndromes.
    Strate LL; Syngal S
    Cancer Causes Control; 2005 Apr; 16(3):201-13. PubMed ID: 15947872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivariate analyses of genomic imbalances in solid tumors reveal distinct and converging pathways of karyotypic evolution.
    Höglund M; Gisselsson D; Mandahl N; Johansson B; Mertens F; Mitelman F; Säll T
    Genes Chromosomes Cancer; 2001 Jun; 31(2):156-71. PubMed ID: 11319803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of comorbidity in head and neck cancer.
    Piccirillo JF
    Laryngoscope; 2000 Apr; 110(4):593-602. PubMed ID: 10764003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecule based diagnosis].
    Akaza H; Ichikawa T; Tsuruo T; Shimada Y; Moriwaki H; Mori M; Noguchi S; Nakamura S; Saijo N; Sone S; Isonishi S; Ohashi Y; Hinotsu S; von Euler M; Blackedge G
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):125-33. PubMed ID: 14750337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Genetic aspects of colorectal cancer].
    Abramowicz M
    Rev Med Brux; 2001 Sep; 22(4):A199-202. PubMed ID: 11680173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
    Lu SL; Akiyama Y; Nagasaki H; Saitoh K; Yuasa Y
    Biochem Biophys Res Commun; 1995 Nov; 216(2):452-7. PubMed ID: 7488133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the human genome in cancer with genomic approaches.
    Scheel JR; Kuo MD
    J Vasc Interv Radiol; 2006 Aug; 17(8):1225-33. PubMed ID: 16923971
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing cancer with a blood draw.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(23):1774-5. PubMed ID: 23213181
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.
    Savonarola A; Palmirotta R; Guadagni F; Silvestris F
    Pharmacogenomics J; 2012 Aug; 12(4):277-86. PubMed ID: 22760589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer.
    Roukos DH
    Expert Rev Mol Diagn; 2013 Jan; 13(1):1-4. PubMed ID: 23256697
    [No Abstract]   [Full Text] [Related]  

  • 38. High-throughput mutational analysis of the human cancer genome.
    Ma PC; Zhang X; Wang ZJ
    Pharmacogenomics; 2006 Jun; 7(4):597-612. PubMed ID: 16753007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of the protein microarray technique and usefulness in individualized molecular tumor therapy]].
    Espina V
    Onkologie; 2005 Oct; 28 Suppl 4():40-2. PubMed ID: 16205105
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacogenomic contribution to drug response.
    Watson RG; McLeod HL
    Cancer J; 2011; 17(2):80-8. PubMed ID: 21427551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.